BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 20412044)

  • 1. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.
    Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C
    Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.
    Rossi A; Maione P; Ferrara ML; Sacco PC; Schettino C; Bareschino MA; Gridelli C
    Curr Med Chem; 2009; 16(30):3919-30. PubMed ID: 19747132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent developments of targeted therapies in the treatment of non-small cell lung cancer.
    Rossi A; Maione P; Colantuoni G; Ferrara C; Rossi E; Guerriero C; Nicolella D; Falanga M; Palazzolo G; Gridelli C
    Curr Drug Discov Technol; 2009 Jun; 6(2):91-102. PubMed ID: 19519336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
    Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F
    Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
    Janning M; Loges S
    Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
    Skouras VS; Maragkos C; Grapsa D; Syrigos KN
    BioDrugs; 2016 Oct; 30(5):421-439. PubMed ID: 27670779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
    Horn L; Sandler AB
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting angiogenesis for treatment of NSCLC brain metastases.
    Schettino C; Bareschino MA; Rossi A; Maione P; Sacco PC; Colantuoni G; Rossi E; Gridelli C
    Curr Cancer Drug Targets; 2012 Mar; 12(3):289-99. PubMed ID: 22229249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting angiogenesis in squamous non-small cell lung cancer.
    Piperdi B; Merla A; Perez-Soler R
    Drugs; 2014 Mar; 74(4):403-13. PubMed ID: 24578213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Subramanian J; Morgensztern D; Govindan R
    Clin Lung Cancer; 2010 Sep; 11(5):311-9. PubMed ID: 20837456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging angiogenesis inhibitors for non-small cell lung cancer.
    Malapelle U; Rossi A
    Expert Opin Emerg Drugs; 2019 Jun; 24(2):71-81. PubMed ID: 31092048
    [No Abstract]   [Full Text] [Related]  

  • 13. [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
    Marco S; Tomasini P; Greillier L; Barlesi F
    Rev Mal Respir; 2011 Dec; 28(10):1216-29. PubMed ID: 22152931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
    Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapies for advanced non-small-cell lung cancer: current status and future implications.
    Custodio A; Méndez M; Provencio M
    Cancer Treat Rev; 2012 Feb; 38(1):36-53. PubMed ID: 21592673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T; Gridelli C; Ciardiello F
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R; Stewart DJ
    Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.
    Scagliotti G; Govindan R
    Oncologist; 2010; 15(5):436-46. PubMed ID: 20427383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
    Keedy VL; Sandler AB
    Cancer Sci; 2007 Dec; 98(12):1825-30. PubMed ID: 17892508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.